- Home
- ANEB
as 01-23-2025 4:00pm EST
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | LAKEWAY |
| Market Cap: | 36.7M | IPO Year: | 2021 |
| Target Price: | $8.00 | AVG Volume (30 days): | 60.6K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.31 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.80 - $3.30 | Next Earning Date: | 02-11-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Anebulo Pharmaceuticals Inc. (ANEB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| English Aron R. | ANEB | Director10% Owner | Dec 23 '24 | Buy | $0.99 | 10,101,010 | $9,999,999.90 | 15,467,300 |
Latest Anebulo Pharmaceuticals Inc. News
ANEB Breaking Stock News: Dive into ANEB Ticker-Specific Updates for Smart Investing
Simply Wall St.
25 days ago
3 US Penny Stocks With Market Caps Under $800M
TipRanks
a month ago
Anebulo Pharmaceuticals collaborates with FDA to advance selonabant
Business Wire
a month ago
Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise
Business Wire
2 months ago
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates
Business Wire
4 months ago
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates
MT Newswires
4 months ago
Top Premarket Decliners
Simply Wall St.
4 months ago
Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation
Business Wire
6 months ago
Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects
Compare ANEB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANEB Anebulo Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.